Fengmin Zhao

Randomized Phase II Trial of Fulvestrant Plus Everolimus or Placebo in Postmenopausal Women With Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer Resistant to Aromatase Inhibitor Therapy: Results of PrE0102.

Kornblum N, Zhao F, Manola J, Klein P, Ramaswamy B, Brufsky A, Stella PJ, Burnette B, Telli M, Makower DF, Cheema P, Truica CI, Wolff AC, Soori GS, Haley B, Wassenaar TR, Goldstein LJ, Miller KD, Sparano JA.

J Clin Oncol. 2018 06 01. 36(16):1556-1563. PMID: 29664714

Fatigue among patients with renal cell carcinoma receiving adjuvant sunitinib or sorafenib: patient-reported outcomes of ECOG-ACRIN E2805 trial.

Zhao F, Cella D, Manola J, DiPaola RS, Wagner LI, Haas NSB.

Support Care Cancer. 2018 06. 26(6):1889-1895. PMID: 29274030

Soluble PD-L1 as a Biomarker in Malignant Melanoma Treated with Checkpoint Blockade.

Zhou J, Mahoney KM, Giobbie-Hurder A, Zhao F, Lee S, Liao X, Rodig S, Li J, Wu X, Butterfield LH, Piesche M, Manos MP, Eastman LM, Dranoff G, Freeman GJ, Hodi FS.

Cancer Immunol Res. 2017 06. 5(6):480-492. PMID: 28522460

Cetuximab Plus Chemoradiotherapy in Immunocompetent Patients With Anal Carcinoma: A Phase II Eastern Cooperative Oncology Group-American College of Radiology Imaging Network Cancer Research Group Trial (E3205).

Garg MK, Zhao F, Sparano JA, Palefsky J, Whittington R, Mitchell EP, Mulcahy MF, Armstrong KI, Nabbout NH, Kalnicki S, El-Rayes BF, Onitilo AA, Moriarty DJ, Fitzgerald TJ, Benson AB.

J Clin Oncol. 2017 Mar. 35(7):718-726. PMID: 28068178

Reply to L.A. Renfro et al.

Zhao F.

J Clin Oncol. 2016 11 10. 34(32):3951. PMID: 27551139

Surrogate End Points and Their Validation in Oncology Clinical Trials.

Zhao F.

J Clin Oncol. 2016 May 01. 34(13):1436-7. PMID: 26951314

Randomized, Placebo-Controlled, Phase III Trial of Yeast-Derived Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) Versus Peptide Vaccination Versus GM-CSF Plus Peptide Vaccination Versus Placebo in Patients With No Evidence of Disease After Complete Surgical Resection of Locally Advanced and/or Stage IV Melanoma: A Trial of the Eastern Cooperative Oncology Group-American College of Radiology Imaging Network Cancer Research Group (E4697).

Lawson DH, Lee S, Zhao F, Tarhini AA, Margolin KA, Ernstoff MS, Atkins MB, Cohen GI, Whiteside TL, Butterfield LH, Kirkwood JM.

J Clin Oncol. 2015 Dec 01. 33(34):4066-76. PMID: 26351350

Long-Term Follow-Up of the E1199 Phase III Trial Evaluating the Role of Taxane and Schedule in Operable Breast Cancer.

Sparano JA, Zhao F, Martino S, Ligibel JA, Perez EA, Saphner T, Wolff AC, Sledge GW, Wood WC, Davidson NE.

J Clin Oncol. 2015 Jul 20. 33(21):2353-60. PMID: 26077235

Anxiety and health-related quality of life among patients with low-tumor burden non-Hodgkin lymphoma randomly assigned to two different rituximab dosing regimens: results from ECOG trial E4402 (RESORT).

Wagner LI, Zhao F, Hong F, Williams ME, Gascoyne RD, Krauss JC, Advani RH, Go RS, Habermann TM, Leach JW, O'Connor B, Schuster SJ, Cella D, Horning SJ, Kahl BS.

J Clin Oncol. 2015 Mar 01. 33(7):740-8. PMID: 25605841

Phase III comparison of tamoxifen versus tamoxifen plus ovarian function suppression in premenopausal women with node-negative, hormone receptor-positive breast cancer (E-3193, INT-0142): a trial of the Eastern Cooperative Oncology Group.

Tevaarwerk AJ, Wang M, Zhao F, Fetting JH, Cella D, Wagner LI, Martino S, Ingle JN, Sparano JA, Solin LJ, Wood WC, Robert NJ.

J Clin Oncol. 2014 Dec 10. 32(35):3948-58. PMID: 25349302